



## Design Therapeutics to Participate in Upcoming Investor Conferences

February 18, 2026

CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present at the following upcoming investor conferences:

- **Oppenheimer 36<sup>th</sup> Annual Healthcare Life Sciences Conference** on Wednesday, February 25, 2026, at 1:20 p.m. ET (virtual)
- **Leerink Partners Global Healthcare Conference** on Tuesday, March 10, 2026, at 2:20 p.m. ET in Miami, FL

Live webcasts of each presentation will be available [here](#) and in the investors section of the company's website at [www.designtx.com](http://www.designtx.com). The webcasts will be archived for at least 30 days following each presentation.

### About Design Therapeutics

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC<sup>®</sup> gene targeted chimera small molecules. The company's GeneTAC<sup>®</sup> molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC<sup>®</sup> programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing DT-818 for myotonic dystrophy type-1, and a program in Huntington's disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit [designtx.com](http://designtx.com).

### Contact:

Renee Leck, THRUST  
[renee@thrustsc.com](mailto:renee@thrustsc.com)